IPI-926

DRUG4 trials

Sponsors

Infinity Pharmaceuticals, Inc.

Conditions

Basal Cell CarcinomaChondrosarcomaConventional ChondrosarcomaFibrosis, Bone MarrowNeoplasmsPrimary Myelofibrosis

Phase 1

A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

CompletedNCT00761696

Infinity Pharmaceuticals, Inc.Neoplasms

Start: 2008-09-30End: 2012-04-30Updated: 2012-06-21

Phase 2

A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

CompletedNCT01310816

Infinity Pharmaceuticals, Inc.Conventional Chondrosarcoma

Start: 2011-02-28End: 2013-12-31Updated: 2013-12-05

A Phase 2 Study With IPI-926 in Patients With Myelofibrosis

CompletedNCT01371617

Infinity Pharmaceuticals, Inc.Fibrosis, Bone Marrow, Primary Myelofibrosis

Start: 2011-10-31End: 2012-08-31Updated: 2012-11-15

Unknown Phase

IPI-926 Extension Protocol for Continuation of Treatment With IPI-926

CompletedNCT01609179

Infinity Pharmaceuticals, Inc.Basal Cell Carcinoma, Chondrosarcoma

Start: 2012-03-31End: 2012-11-30Updated: 2012-11-14

Related Papers

A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis.

Journal of Clinical Oncology2014-05-203 citations